Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Ostadal, Petr ^a   Vondrakova, Dagmar ^a   Kruger, Andreas ^a   Janotka, Marek ^a   Psotova, Hana ^a   Prucha, Miroslav ^a  

^a NA HOMOLCE HOSPITAL   (Czech Republic)

Author keywords

Acute coronary syndrome; C reactive protein; Lipoprotein associated phospholipase A2; Low density lipoprotein; Troponin I

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; ENZYME BLOOD LEVEL; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION CUTE CORONARY SYNDROME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TROPONIN;

EID: 84868518564     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-153     Document Type: Article

References (12)

1. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. Colley KJ, Wolfert RL, Cobble ME, EPMA J 2011 2 1 27 38 10.1007/s13167-011-0063-4 21654904
2. Lp-PLA- a novel risk factor for high-risk coronary and carotid artery disease. Epps KC, Wilensky RL, J Intern Med 2011 269 1 94 106 10.1111/j.1365-2796.2010.02297.x 21054587
3. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Zalewski A, Macphee C, Arterioscler Thromb Vasc Biol 2005 25 5 923 931 10.1161/01.ATV.0000160551.21962. a7 15731492 (Pubitemid 40627835)
4. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R, Arterioscler Thromb Vasc Biol 2006 26 11 2523 2529 10.1161/01.ATV.0000244681.72738.bc 16960105 (Pubitemid 44607475)
5. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, et al. Eur J Cardiovasc Prev Rehabil 2007 14 1 3 11 17301621
6. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, et al. Lancet 2010 375 9725 1536 1544 20435228
7. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of scotland coronary prevention study group. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, et al. N Engl J Med 2000 343 16 1148 1155 10.1056/NEJM200010193431603 11036120
8. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Circulation 2006 113 14 1745 1752 10.1161/CIRCULATIONAHA.105.612630 16537575 (Pubitemid 43958467)
9. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL, Arterioscler Thromb Vasc Biol 2006 26 11 2517 2522 10.1161/01.ATV.0000240406.89440.0c 16902161 (Pubitemid 44607474)
10. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Oldgren J, James SK, Siegbahn A, Wallentin L, Eur Heart J 2007 28 6 699 704 10.1093/eurheartj/ehl565 17314110 (Pubitemid 46439239)
11. Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. Vondrakova D, Ostadal P, Kruger A, Lipids Health Dis 2010 9 71 10.1186/1476-511X-9-71 20630099
12. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, Martinkovicova L, Vojacek J, Mol Cell Biochem 2007 306 1-2 19 23 17653509 (Pubitemid 350001812)